Overview
- Peptide (C)EDVRDDPVLRRLE, corresponding to amino acid residues 233-245 of rat KCNS1 (Accession O88758). 1st extracellular loop.
- Rat and mouse brain membranes and human HL-60 promyelocytic leukemia cell lines (1:200).
- Western blot analysis of mouse (lanes 1 and 4), and rat (lanes 2 and 5) brain membranes and human HL-60 promyelocytic leukemia cell lysates (lanes 3 and 6):1-3. Anti-KCNS1 (KV9.1) (extracellular) Antibody (#APC-131), (1:200).
4-6. Anti-KCNS1 (KV9.1) (extracellular) Antibody, preincubated with KCNS1/Kv9.1 (extracellular) Blocking Peptide (#BLP-PC131).
K+ channels are transmembrane proteins expressed in many excitable and non-excitable cells. Functional entities are formed by the tetrameric assembly of α subunits which could be done in a homomeric or heteromeric fashion. In addition, the association of β subunits is also required for the proper function of K+channels. Various splice variants are also expressed, thereby complicating the picture1,2.
K+ channels belonging to the KV9 subfamily resemble the delayed-rectifier class of K+ channel a subunits. These channels include six transmembrane domains, an ion selective pore, a leucine zipper and positively charged amino acids in S4 the voltage sensor domain. Interestingly, both KV9.1 and KV9.3 channels are electrically silent delayed rectifying K+ channels. However, they are responsible for modifying the activity of other K+ channels such as that of KV2.1, yielding currents different from those of KV2.1 on its own1.
KV9.1 is mainly expressed in the brain, human lens epithelial cells, kidney, prostate and testis. That of KV9.3 is more generalized and ubiquitous1.
Interestingly, a polymorphism in the gene encoding for KV9.1 was identified and associated with high risks of suffering from neuropathic pain3. Evidently, additional work needs to be done to evaluate and decipher the role of KV9.1 (if at all) in chronic pain states.